Publications

(Displaying in Reverse Chronological Order)

  1. Research
  2. Publications
  3. Publications
2311
Varma MV, Khandavilli S and Panchagnula R. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport Molecular Pharmaceutics 2005, 2, 21-12.
2312
Varma MV, Sarkar M, Kapoor N and Panchagnula R. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs 1 Simultaneous determination of quinidine and permeability markers in rat in situ perfusion samples Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2005, 816, 243-249.
2313
Vats P and Banerjee UC. Biochemical characterisation of extracellular phytase (myo-inositol hexakisphosphate phosphohydrolase) from a hyper-producing strain of Aspergillus niger van Teighem Journal of Industrial Microbiology and Biotechnology 2005, 32, 141-147.
2314
Verma RK and Garg S. Selection of excipients for extended release formulations of glipizide through drug-excipient compatibility testing Journal of Pharmaceutical and Biomedical Analysis 2005, 38, 633-644.
2315
Visalakshi NA, Mariappan TT, Bhutani H and Singh S. Behavior of moisture gain and equilibrium moisture contents (EMC) of various drug substances and correlation with compendial information on hygroscopicity and loss on drying Pharmaceutical Development and Technology 2005, 10, 489-497.
2316
Wadhwa LK, Ravikumar K, Saxena R, Singh S and Swamy GYSK. (2R*,3R*,6S*)-N,6-Bis(4-fluorophenyl)-2-(4-hydroxyphenyl)-3,4,5,6-tetrahydro-2H-pyran-3-carboxamide Acta Crystallographica Section E 2005, E61, o3608-o3610..
2317
Aboye TL, Sobhia ME and Bharatam PV. 3D-QSAR studies of pyruvate dehydrogenase kinase inhibitors based on a divide and conquer strategy Bioorganic & Medicinal Chemistry 2004, 12, 2709-2715.
2318
Agrawal S and Panchagnula R. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations International Journal of Pharmaceutics 2004, 287, 97-112.
2319
Agrawal S and Panchagnula R. In vitro analysis of rifampicin and its effect on quality control tests of rifampicin containing dosage forms Die Pharmazie 2004, 59, 775-785.
2320
Agrawal S and Panchagnula R. In vitro evaluation of fixed dose combination tablets of anti-tuberculosis drugs after real time storage at ambient conditions Die Pharmazie 2004, 59, 782-785.
2321
Agrawal S, Ashokraj Y, Bharatam PV, Pillai PO and Panchagnula R. Solid-state characterization of rifampicin samples and its Biopharmaceutic relevance European Journal of Pharmaceutical Sciences 2004, 22, 127-144.
2322
Agrawal S, Singh I, Kaur KJ, Bhade S, Kaul CL and Panchagnula R. Bioequivalence trials of rifampicin containing formulations: extrinsic and intrinsic factors in the absorption of rifampicin Pharmacological Research 2004, 50, 317-327.
2323
Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL and Panchagnula R. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels International Journal of Pharmaceutics 2004, 276, 41-49.
2324
Arun KHS, Kaul CL and Ramarao P. High glucose concentration augments angiotensin II mediated contraction via AT1 receptors in rat thoracic aorta Pharmacological Research 2004, 50, 561-568.
2325
Arun KHS, Kaul CL and Ramarao P. Tempol augments angiotensin II induced AT2-receptor mediated relaxation in diabetic rat thoracic aorta Journal of Hypertension 2004, 22, 2143-2152.
Information: Duration to be uploaded/incorporated on archival site after the completion of process is 12 months.

2627|155|15